Post

Novartis will see modest boost to blood cancer portfolio with MorphoSys acquisition

On 4 February 2024, Novartis announced its acquisition of the prominent biopharmaceutical company MorphoSys AG. This deal provides Novartis with …

EVŌQ Nano’s antimicrobial platform proves effective against HAIs

US-based nanoscience company EVŌQ Nano’s antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated …

Magentiq’s AI-aided colonoscopy tool increases adenoma detection by 7%

Israel-based Magentiq Eye has published data from a clinical trial assessing its computer-aided detection colonoscopy tool, Magentiq-Colo CADe. The results …

Notable Labs hopes for success with Boehringer’s failed AML drug

California-based Notable Labs is hoping for success as it launches a Phase II trial of Boehringer Ingelheim’s failed candidate volasertib …

MAIA Biotechnology concludes subject enrolment in NSCLC therapy trial

MAIA Biotechnology has announced the completion of subject enrolment in its Phase II THIO-101 clinical trial of THIO (6-thio-dG or …